Price target
127,764.710.000.00%
The 17 analysts offering 1 year price forecasts for 326030 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 17 analysts giving stock ratings to 326030 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
326030 EPS for the last quarter is 123.44 KRW despite the estimation of 123.44 KRW. In the next quarter EPS is expected to reach 67.49 KRW. Track more of SK BIOPHARMACEUTICALS financials and stay on top of what is up with the company.
In the next quarter SK BIOPHARMACEUTICALS revenue is expected to reach 149.98 B KRW. Check out SK BIOPHARMACEUTICALS revenue and earnings and make informed decisions.
According to analysts, 326030 price target is 127,764.71 KRW with a max estimate of 150,000.00 KRW and a min estimate of 57,000.00 KRW. Check if this forecast comes true in a year, meanwhile watch SK BIOPHARMACEUTICALS stock price chart and keep track of the current situation with 326030 news and stock market news.
We've gathered opinions of 17 analysts rating 326030 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.